STOCK TITAN

Voyager Therapeutics Inc - VYGR STOCK NEWS

Welcome to our dedicated news page for Voyager Therapeutics (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Voyager Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Voyager Therapeutics's position in the market.

Rhea-AI Summary
Voyager Therapeutics announces seven data presentations at ASGCT Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.1%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.79%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.89%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
conferences
Voyager Therapeutics Inc

Nasdaq:VYGR

VYGR Rankings

VYGR Stock Data

519.11M
36.95M
17.33%
48.78%
4.17%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About VYGR

voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.